A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma.

Rohan Palanki Kelsey L Swingle Michael J Mitchell

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

A microencapsulated, cell-based IL2 cytokine factory was recently developed, and the safety and efficacy of this platform in a mouse model of mesothelioma were demonstrated. This platform has the potential to overcome current challenges in the delivery of therapeutic cytokines for cancer immunotherapy. See related article by Nash et al., p. 5121.

Keyphrases

mouse model
high throughput
single cell
cell therapy
stem cells
human health
bone marrow
combination therapy
climate change